146 related articles for article (PubMed ID: 25279584)
1. Clomipramine demethylation rate is important on the outcome of obsessive-compulsive disorder treatment.
Marcourakis T; Bernik MA; Lotufo Neto F; Gedanke Shavitt R; Gorenstein C
Int Clin Psychopharmacol; 2015 Jan; 30(1):43-8. PubMed ID: 25279584
[TBL] [Abstract][Full Text] [Related]
2. Plasma clomipramine levels in adult patients with obsessive-compulsive disorder.
Marazziti D; Baroni S; Faravelli L; Giannaccini G; Massimetti G; Palego L; Catena-Dell'Osso M
Int Clin Psychopharmacol; 2012 Jan; 27(1):55-60. PubMed ID: 21979789
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
[TBL] [Abstract][Full Text] [Related]
4. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder.
Mavissakalian M; Jones B; Olson S; Perel JM
Psychopharmacol Bull; 1990; 26(1):119-22. PubMed ID: 2371366
[TBL] [Abstract][Full Text] [Related]
5. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
Albert U; Aguglia E; Maina G; Bogetto F
J Clin Psychiatry; 2002 Nov; 63(11):1004-9. PubMed ID: 12444814
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of clomipramine and desmethylclomipramine and clinical improvement in panic disorder.
Marcourakis T; Gorenstein C; Ramos RT; da Motta Singer J
J Psychopharmacol; 1999; 13(1):40-4. PubMed ID: 10221358
[TBL] [Abstract][Full Text] [Related]
7. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
Luscombe DK; Wright J; Stern RS; Mawson D; Marks IM
Postgrad Med J; 1980; 56 Suppl 1():140-3. PubMed ID: 7393825
[TBL] [Abstract][Full Text] [Related]
9. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
Mundo E; Bareggi SR; Pirola R; Bellodi L; Smeraldi E
J Clin Psychopharmacol; 1997 Feb; 17(1):4-10. PubMed ID: 9004050
[TBL] [Abstract][Full Text] [Related]
10. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
Brown JT; Schneiderhan M; Eum S; Bishop JR
Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
[TBL] [Abstract][Full Text] [Related]
11. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype.
Haffen E; Vandel P; Broly F; Vandel S; Sechter D; Bizouard P; Bechtel PR
Pharmacopsychiatry; 1999 Nov; 32(6):232-4. PubMed ID: 10599932
[TBL] [Abstract][Full Text] [Related]
12. Citalopram pharmacokinetic interaction with clomipramine. UDP-glucuronosyltransferase inhibition? A case report.
Haffen E; Vandel P; Bonin B; Vandel S
Therapie; 1999; 54(6):768-70. PubMed ID: 10709456
[No Abstract] [Full Text] [Related]
13. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.
Diniz JB; Shavitt RG; Pereira CA; Hounie AG; Pimentel I; Koran LM; Dainesi SM; Miguel EC
J Psychopharmacol; 2010 Mar; 24(3):297-307. PubMed ID: 19164490
[TBL] [Abstract][Full Text] [Related]
14. Treatment of obsessive-compulsive disorder using clomipramine in a very old patient.
Trappler B
Ann Pharmacother; 1999 Jun; 33(6):686-90. PubMed ID: 10410180
[TBL] [Abstract][Full Text] [Related]
15. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
16. A preliminary report on clinical response and plasma levels of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
Stern RS; Cobb JP; Marks IM; Jones RB; Luscombe DK
Postgrad Med J; 1977; 53 Suppl 4():97-103. PubMed ID: 341110
[No Abstract] [Full Text] [Related]
17. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
Zohar J; Judge R
Br J Psychiatry; 1996 Oct; 169(4):468-74. PubMed ID: 8894198
[TBL] [Abstract][Full Text] [Related]
18. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis.
Stern RS; Marks IM; Wright J; Luscombe DK
Postgrad Med J; 1980; 56 Suppl 1():134-9. PubMed ID: 7393824
[TBL] [Abstract][Full Text] [Related]
19. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
Mavissakalian MR; Jones B; Olson S; Perel JM
J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
[TBL] [Abstract][Full Text] [Related]
20. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG).
Clin Pharmacol Ther; 1999 Aug; 66(2):152-65. PubMed ID: 10460069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
